Literature DB >> 18390527

Polymyalgia rheumatica.

Clement J Michet1, Eric L Matteson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18390527      PMCID： PMC2287267          DOI： 10.1136/bmj.39514.653588.80

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  21 in total

Review 1.  Polymyalgia rheumatica and giant-cell arteritis.

Authors:  Carlo Salvarani; Fabrizio Cantini; Luigi Boiardi; Gene G Hunder
Journal:  N Engl J Med       Date:  2002-07-25       Impact factor: 91.245

2.  The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain.

Authors:  M A Gonzalez-Gay; C Garcia-Porrua; C Salvarani; I Olivieri; G G Hunder
Journal:  J Rheumatol       Date:  2000-09       Impact factor: 4.666

Review 3.  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

Authors: 
Journal:  Arthritis Rheum       Date:  2001-07

4.  Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis.

Authors:  A Proven; S E Gabriel; W M O'Fallon; G G Hunder
Journal:  J Rheumatol       Date:  1999-06       Impact factor: 4.666

Review 5.  Imaging in rheumatoid arthritis--why MRI and ultrasonography can no longer be ignored.

Authors:  Mikkel Ostergaard; Marcin Szkudlarek
Journal:  Scand J Rheumatol       Date:  2003       Impact factor: 3.641

Review 6.  Giant-cell arteritis and polymyalgia rheumatica.

Authors:  Cornelia M Weyand; Jörg J Goronzy
Journal:  Ann Intern Med       Date:  2003-09-16       Impact factor: 25.391

7.  Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial.

Authors:  Roberto Caporali; Marco A Cimmino; Gianfranco Ferraccioli; Roberto Gerli; Catherine Klersy; Carlo Salvarani; Carlomaurizio Montecucco
Journal:  Ann Intern Med       Date:  2004-10-05       Impact factor: 25.391

8.  Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA.

Authors:  Michele F Doran; Cynthia S Crowson; W Michael O'Fallon; Gene G Hunder; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2002-08       Impact factor: 4.666

9.  Prognosis and management of polymyalgia rheumatica.

Authors:  J G Jones; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1981-02       Impact factor: 19.103

10.  EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).

Authors:  B F Leeb; H A Bird; G Nesher; I Andel; W Hueber; D Logar; C M Montecucco; J Rovensky; J Sautner; M Sonnenblick
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103
View more
  12 in total

1.  Diagnosis and management of polymyalgia rheumatica.

Authors:  Toby Helliwell; Samantha L Hider; Kevin Barraclough; Bhaskar Dasgupta; Christian D Mallen
Journal:  Br J Gen Pract       Date:  2012-05       Impact factor: 5.386

2.  Presentations of perforated colonic pathology in patients with polymyalgia rheumatica: two case reports.

Authors:  Punyanganie de Silva; Nagarajan Pranesh; Guy Vautier
Journal:  J Med Case Rep       Date:  2010-09-06

Review 3.  Clinical features of polymyalgia rheumatica and giant cell arteritis.

Authors:  Carlo Salvarani; Nicolò Pipitone; Annibale Versari; Gene G Hunder
Journal:  Nat Rev Rheumatol       Date:  2012-07-24       Impact factor: 20.543

Review 4.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

5.  Polymyalgia rheumatica presenting as nocturnal fever of undetermined origin.

Authors:  Husayn Al Mahdy; Sarah Martindale
Journal:  JRSM Short Rep       Date:  2010-06-30

6.  The risk of polymyalgia rheumatica in older adults with gout: a Medicare claims study.

Authors:  Jasvinder A Singh; John D Cleveland
Journal:  Rheumatol Adv Pract       Date:  2018-06-20

7.  Induction of remission is difficult due to frequent relapse during tapering steroids in Korean patients with polymyalgia rheumatica.

Authors:  Hyoun-Ah Kim; Jisoo Lee; You-Jung Ha; Sang-Hyon Kim; Chan-Hee Lee; Hyo-Jin Choi; Han-Joo Baek; Mie Jin Lim; Won Park; Sungiae Choi; Yeon-Sik Hong; Yoo-Hyun Lee; Bo-Ram Koh; Chang-Hee Suh
Journal:  J Korean Med Sci       Date:  2011-12-19       Impact factor: 2.153

8.  The rate of polymyalgia rheumatica (PMR) and remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome in a clinic where primary care physicians are working in Japan.

Authors:  Toshikatsu Okumura; Satoshi Tanno; Masumi Ohhira; Tsukasa Nozu
Journal:  Rheumatol Int       Date:  2011-03-24       Impact factor: 2.631

9.  Risk of vascular events in patients with polymyalgia rheumatica.

Authors:  Adam T Hancock; Christian D Mallen; Sara Muller; John Belcher; Edward Roddy; Toby Helliwell; Samantha L Hider
Journal:  CMAJ       Date:  2014-07-28       Impact factor: 8.262

10.  Polymyalgia rheumatica: diagnosis, prescribing, and monitoring in general practice.

Authors:  Toby Helliwell; Samantha Lara Hider; Christian David Mallen
Journal:  Br J Gen Pract       Date:  2013-05       Impact factor: 5.386
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.